BioXcel Therapeutics (BTAI) Gains from Sales and Divestitures (2023 - 2026)
BioXcel Therapeutics (BTAI) recorded quarterly Gains from Sales and Divestitures of $2.0 in Q1 2026, down 99.99% quarter-over-quarter from $24000.0 in Q4 2025, and little changed on a YoY basis from $2.0 in Q1 2025.
BioXcel Therapeutics (BTAI) Gains from Sales and Divestitures (2023 - 2026) Analysis & Trends
BioXcel Therapeutics' Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $2.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures changed 0.0% year-over-year to $2.0; the TTM figure through Mar 2026 stood at $2.0 (changed 0.0% YoY), while the FY2025 annual figure was $24000.0, changed N/A from the prior year.
- Gains from Sales and Divestitures was $2.0 for Q1 2026 at BioXcel Therapeutics, down from $24000.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $67000.0 in Q4 2023 to a low of $2.0 in Q1 2025.
- Historically, Gains from Sales and Divestitures has averaged $30100.9 across 4 years, with a median of $24500.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Gains from Sales and Divestitures changed 0.0% in 2024, then plunged 74.55% in 2025.
- A 4-year view of Gains from Sales and Divestitures shows it stood at $67000.0 in 2023, then declined by 17.91% to $55000.0 in 2024, then plunged by 56.36% to $24000.0 in 2025, then sank by 99.99% to $2.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $2.0 (Q1 2026), $24000.0 (Q4 2025), and $5.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | BioXcel Therapeutics | 25.81 Mn | 25.81 Mn | -77,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.00 |
| Mar 31, 2026 | 2.00 |
| Dec 31, 2025 | 24,000.00 |
| Dec 31, 2025 | 24,000.00 |
| Sep 30, 2025 | 5.00 |
| Sep 30, 2025 | 5.00 |
| Jun 30, 2025 | 14,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 2.00 |
| Mar 31, 2025 | 2.00 |
| Jun 30, 2024 | 55,000.00 |
| Jun 30, 2024 | 55,000.00 |
| Dec 31, 2023 | 67,000.00 |
| Dec 31, 2023 | 67,000.00 |
| Sep 30, 2023 | 61,000.00 |
| Sep 30, 2023 | 61,000.00 |
| Jun 30, 2023 | 55,000.00 |
| Jun 30, 2023 | 55,000.00 |
| Mar 31, 2023 | 25,000.00 |
| Mar 31, 2023 | 25,000.00 |